Hoffmann-la Roche

This study tested whether adding atezolizumab to cabozantinib works better than cabozantinib alone for people with advanced kidney cancer that got worse after immunotherapy. The trial planned to enroll 522 participants but was terminated early. The goal was to see if the combinat…

This study tested several drug combinations in 40 people with advanced stomach or gastroesophageal junction cancer that had not been treated before. The goal was to see how well the treatments shrank tumors and how safe they were. The study was flexible, allowing new combinations…

This early-stage study tested a new medicine called RO7565020 in healthy people and those with chronic hepatitis B. The goal was to check safety and how the drug moves through the body. The trial was stopped early, so results are limited.

This study tested a new targeted pill, pralsetinib, against standard chemotherapy for people with a specific type of advanced lung cancer (RET fusion-positive) who had not yet received treatment. The goal was to see if the targeted drug could delay cancer growth better than chemo…

This study looked at different immunotherapy drug combinations for people with advanced non-small cell lung cancer that had spread. It included two groups: those who had not yet received treatment and those whose cancer had worsened after standard therapies. The goal was to see i…

This study tested a drug called basmisanil in children aged 2 to 14 with Dup15q syndrome, a rare genetic condition that causes developmental delays. The goal was to see if the drug could improve daily living skills by targeting a specific brain receptor. Only 7 children enrolled,…

This study looked at whether giving two immunotherapy drugs (tiragolumab and atezolizumab) before and after surgery, with or without chemotherapy, could help people with early-stage lung cancer. The trial aimed to see if the treatment was safe and helped shrink tumors before surg…

This study looked at whether digital health tools (like smartphone apps) could help people on cancer treatment feel better and use fewer healthcare resources. It included 49 adults with certain cancers who were starting or had completed treatment. The study was stopped early, so …